Pharmacotherapy and ROP: Going Back to the Basics

Area of Science:

• Ophthalmology
• Neonatology
• Developmental Biology

Background:

• Retinopathy of prematurity (ROP) is a significant cause of vision impairment in preterm infants globally.
• Understanding of ROP pathophysiology has advanced through animal models and clinical studies since its initial description.
• Current treatments primarily involve laser therapy, but pharmacologic interventions are increasingly utilized.

Purpose of the Study:

• To summarize the current understanding of Retinopathy of prematurity pathophysiology.
• To discuss contemporary therapeutic strategies for ROP, focusing on pharmacotherapy.
• To review emerging targets for pharmacologic treatment of ROP.

Main Methods:

• Review of data from animal models of ROP.
• Analysis of findings from clinical trials in ROP.
• Synthesis of current literature on ROP pathophysiology and treatment.

Main Results:

• Animal models have been crucial in elucidating ROP disease mechanisms.
• Pharmacotherapy is becoming a more common treatment modality for ROP.
• New targets for drug development in ROP treatment are emerging.

Conclusions:

• Continued research into ROP pathophysiology is essential for advancing treatment.
• Pharmacologic agents represent a growing and important component of ROP management.
• Future therapies may offer improved outcomes for preterm infants at risk of ROP.